How Analysts Feel About Canadian Natural Resource Ltd (USA) (NYSE:CNQ)?

Ajustar Comentario Impresión

In the last quarter, insiders purchased 120,000 shares of company stock valued at $4,447,400 and sold 81,750 shares valued at $3,501,863. Cdn Natural Res now has $36.25 billion valuation. Scotiabank lifted their target price on shares of Canadian Natural Resources Limited from C$45.00 to C$50.00 and gave the company an "outperform" rating in a report on Friday, March 10th. It has underperformed by 6.38% the S&P500. The company has a market cap of $32.83 billion, a P/E ratio of 299.90 and a beta of 1.41. The Firm develops and commercializes pharmaceuticals for various diseases and medical conditions.

Beutel Goodman & Co Ltd increased Agrium Inc (NYSE:AGU) stake by 285,490 shares to 4.29M valued at $431.67M in 2016Q4. It also reduced its holding in Howard Hughes Corp (NYSE:HHC) by 142,971 shares in the quarter, leaving it with 146,029 shares, and cut its stake in Barclays Bk Plc (INP). Ingersoll (NYSE:IR) was raised too.

Jarislowsky Fraser Ltd raised its position in shares of Canadian Natural Resources Limited (NYSE:CNQ) (TSE:CNQ) by 0.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. Therefore 75% are positive. Canadian Natural Resources Limited has a dividend payout ratio of 84.6% indicating that its dividend is now covered by earnings, but may not be in the future if the company's earnings decline. TheStreet raised Canadian Natural Resources Limited from a "d+" rating to a "c-" rating in a report on Wednesday, April 12th. Finally, Raymond James Financial, Inc. lifted their price target on Canadian Natural Resources Limited from C$51.00 to C$53.00 and gave the company an "outperform" rating in a research report on Friday, March 10th. The rating was initiated by Bank of America with "Buy" on Friday, August 19. Finally, Canaccord Genuity reissued a "buy" rating and issued a $47.00 price objective on shares of Canadian Natural Resources Limited in a report on Saturday, March 11th. RBC Capital Markets maintained it with "Outperform" rating and $39 target in Friday, November 6 report. One equities research analyst has rated the stock with a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company. Macquarie Research downgraded Canadian Natural Resource Ltd (USA) (NYSE:CNQ) on Friday, January 8 to "Neutral" rating. JP Morgan has "Neutral" rating and $30 target. Raymond James upgraded the stock to " rating in Friday, August 7 report. The company was downgraded on Tuesday, January 12 by Morgan Stanley.

Amici Capital Llc holds 13.19% of its portfolio in BioMarin Pharmaceutical Inc. for 409,818 shares. Walthausen & Co. Llc owns 2.40 million shares or 0.93% of their U.S. portfolio. The New Jersey-based New Jersey Better Educational Savings Trust has invested 0.32% in the stock. Tang Capital Management Llc, a California-based fund reported 90,215 shares. About shares traded. BioMarin Pharmaceutical Inc. About shares traded. Great Lakes Dredge & Dock Corporation (GLDD) has risen 5.20% since June 13, 2016 and is uptrending. It has underperformed by 11.41% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.